Skip to main content
. 2019 Jun 22;28(R1):R80–R87. doi: 10.1093/hmg/ddz138

Figure 2.

Figure 2

Current status of molecular therapies for selected triplet repeat disorders. The information included in this figure is inferred from published or publicly available information. Therapeutic ASOs are taking the lead in the ‘race’ to commercialization for TRDs.